emedastine has been researched along with Pruritus in 7 studies
emedastine: structure given in first source
emedastine : 1-Methyl-1,4-diazepane in which the hydrogen attached to the nitrogen at position 4 is substituted by a 1-(2-ethoxyethyl)-1H-benzimidazol-2-yl group. A relatively selective histamine H1 antagonist, it is used as the difumatate salt for allergic rhinitis, urticaria, and pruritic skin disorders, and in eyedrops for the symptomatic relief of allergic conjuntivitis.
Pruritus: An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)." | 9.14 | Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. ( Akman, A; Akova, YA; Borazan, M; Erbek, SS; Karalezli, A; Kiyici, H, 2009) |
| " The aims of the present study were to establish whether there is a rapid effect of eyedrops containing the selective H1 receptor blocker emedastine on acute seasonal allergic conjunctivitis and, if so, the time required for this effect to develop." | 9.10 | [Effects of emedastine eyedrops on acute seasonal allergic conjunctivitis in children]. ( Endre, L, 2003) |
| "In a prospective, multicenter, randomized, double-masked, parallel group study, 222 patients with allergic conjunctivitis were randomized (221 received treatment) to either emedastine or levocabastine, instilled twice daily for 6 weeks." | 9.09 | Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. ( Abrantes, P; Apel, AJ; Brancato, R; Carmichael, TR; Cerqueti, PM; Ciprandi, G; Coroneo, MT; Coster, DJ; Easty, DL; Estivin-Ebrardt, C; Harrisberg, CJ; Kent-Smith, BT; Knorr, M; Leonardi, A; Martinez, M; Modorati, G; Nemeth-Wasmer, G; Partouche, P; Secchi, A; Verin, P, 2001) |
| "During the first experiment 20 children (suffering from acute seasonal allergic conjunctivitis) had received Emadine eye drop (containing emedastine difumarate, an H1 antihistamine agent)." | 7.74 | [The prompt effect of emedastine eye drop and the safety of its permanent use in children suffering from acute seasonal allergic conjunctivitis]. ( Endre, L, 2007) |
| "We aimed to compare the clinical efficacy and ocular surface variables of olopatadine, ketotifen fumarate, epinastine, emedastine and fluorometholone acetate ophthalmic solutions in preventing the signs and symptoms of seasonal allergic conjunctivitis (SAC)." | 5.14 | Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. ( Akman, A; Akova, YA; Borazan, M; Erbek, SS; Karalezli, A; Kiyici, H, 2009) |
| " The aims of the present study were to establish whether there is a rapid effect of eyedrops containing the selective H1 receptor blocker emedastine on acute seasonal allergic conjunctivitis and, if so, the time required for this effect to develop." | 5.10 | [Effects of emedastine eyedrops on acute seasonal allergic conjunctivitis in children]. ( Endre, L, 2003) |
| "The results of this study suggest that emedastine and ketotifen are not significantly different with respect to anti-itching efficacy in the CAC model of acute allergic conjunctivitis." | 5.10 | Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the human conjunctival allergen challenge model. ( Bensch, G; D'Arienzo, PA; Leonardi, A, 2002) |
| "In a prospective, multicenter, randomized, double-masked, parallel group study, 222 patients with allergic conjunctivitis were randomized (221 received treatment) to either emedastine or levocabastine, instilled twice daily for 6 weeks." | 5.09 | Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. ( Abrantes, P; Apel, AJ; Brancato, R; Carmichael, TR; Cerqueti, PM; Ciprandi, G; Coroneo, MT; Coster, DJ; Easty, DL; Estivin-Ebrardt, C; Harrisberg, CJ; Kent-Smith, BT; Knorr, M; Leonardi, A; Martinez, M; Modorati, G; Nemeth-Wasmer, G; Partouche, P; Secchi, A; Verin, P, 2001) |
| "During the first experiment 20 children (suffering from acute seasonal allergic conjunctivitis) had received Emadine eye drop (containing emedastine difumarate, an H1 antihistamine agent)." | 3.74 | [The prompt effect of emedastine eye drop and the safety of its permanent use in children suffering from acute seasonal allergic conjunctivitis]. ( Endre, L, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borazan, M | 1 |
| Karalezli, A | 1 |
| Akova, YA | 1 |
| Akman, A | 1 |
| Kiyici, H | 1 |
| Erbek, SS | 1 |
| Endre, L | 2 |
| Andoh, T | 1 |
| Kuraishi, Y | 1 |
| Verin, P | 1 |
| Easty, DL | 1 |
| Secchi, A | 1 |
| Ciprandi, G | 1 |
| Partouche, P | 1 |
| Nemeth-Wasmer, G | 1 |
| Brancato, R | 1 |
| Harrisberg, CJ | 1 |
| Estivin-Ebrardt, C | 1 |
| Coster, DJ | 1 |
| Apel, AJ | 1 |
| Coroneo, MT | 1 |
| Knorr, M | 1 |
| Carmichael, TR | 1 |
| Kent-Smith, BT | 1 |
| Abrantes, P | 1 |
| Leonardi, A | 2 |
| Cerqueti, PM | 1 |
| Modorati, G | 1 |
| Martinez, M | 1 |
| Takizawa, T | 1 |
| Matsumoto, J | 1 |
| Tohma, T | 1 |
| Kanke, T | 1 |
| Wada, Y | 1 |
| Nagao, M | 1 |
| Inagaki, N | 1 |
| Nagai, H | 1 |
| Zhang, MQ | 1 |
| Timmerman, H | 1 |
| D'Arienzo, PA | 1 |
| Bensch, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Trial Comparing Olopatadine 0.1% Ophthalmic Solution With Hylo-Dual Ophthalmic Preparation in Children With Seasonal Allergic Conjunctivitis[NCT03186755] | Phase 4 | 42 participants (Anticipated) | Interventional | 2017-06-11 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for emedastine and Pruritus
3 other studies available for emedastine and Pruritus
| Article | Year |
|---|---|
[The prompt effect of emedastine eye drop and the safety of its permanent use in children suffering from acute seasonal allergic conjunctivitis].
Topics: Acute Disease; Adolescent; Adult; Anti-Allergic Agents; Benzimidazoles; Child; Conjunctivitis, Aller | 2007 |
Involvement of blockade of leukotriene B(4) action in anti-pruritic effects of emedastine in mice.
Topics: Animals; Anti-Allergic Agents; Benzimidazoles; Dose-Response Relationship, Drug; Histamine; Injectio | 2000 |
VUF-K-8788, a periphery-selective histamine H1 antagonist with anti-pruritic activities.
Topics: Animals; Anti-Allergic Agents; Behavior, Animal; Benzimidazoles; Capillary Permeability; Guinea Pigs | 2001 |